GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.

Slides:

Advertisements

Similar presentations

 GLP -1 (gut hormone) + GIP = incretin effect =Augmentation of insulin after oral glucose  Type 2 diabetics little incretin effect  Reduced GLP-1 secretion.

Advertisements

©2006, ICHE Development of Therapeutic Agents Based on the GLP-1 Pathway Terry W. Sherraden, MD, FACE Tallahassee Endocrine Associates Tallahassee Florida.

Incretins: The New Frontier in Diabetes Therapy

Faculty Disclosure Mikayla Spangler, PharmD, BCPS Dr. Spangler has listed no financial interest/arrangement that would be considered a conflict of interest.

Bydureon ® Educate By Expert toolkit Scientific slides: GLP-1 receptor agonists and the discovery of exenatide GLP-1, glucagon-like peptide-1. Developed.

Recovery of the β–cell function both in new and long-standing type 2 diabetic patients through long-term treatment with continuous subcutaneous insulin.

Prescribing information can be found at the end of this slide deck.

Consider this Combo: GLP-1 Receptor Agonists and Basal Insulin Matt Heinsen, PharmD PGY2 Pharmacotherapy Resident Butler University & Community Health.

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 1.

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 4 of 4.

Journal Club 2009 年 1 月 29 日（木） 8 ： 20 ～ 8 ： 50 B 棟 8 階カンファレンスルーム薬剤部 TTSP 石井英俊.

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.

ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.

Therapy of Type 2 Diabetes Mellitus: UPDATE

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.

JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA Tablets contain sitagliptin.

Part 2 of 2.  GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 4 of 5.

 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.

SGLT2 INHIBITION: A NOVEL TREATMENT STRATEGY FOR TYPE 2 DIABETES MELLITUS.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

Diabetes Prevention Program (DPP)

Contributions to Type 2 Diabetes. Glucose in balance meal Time in minutes Blood glucose levels, mg/dL Insulin levels, uU/mL Glucagon.

Journal Club 9/15/11 Sanaz Sakiani, MD 1 st Year Endocrine Fellow Combining Basal Insulin Analogs with Glucagon-Like Peptide-1 Mimetics.

Gerti Tashko, M.D. DM Journal Club 12/16/2010. The use of exenatide with insulin is not FDA approved. The study was designed to evaluate if exenatide.

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-Week,

Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy Department of Internal.

GLP-1 agonists Ian Gallen Consultant Community Diabetologist

Part 5. Insulin Resistance and  -Cell Dysfunction: Summary Individuals with impaired glucose tolerance –Are maximally or near-maximally insulin resistant.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions?

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.

Placebo Metformin ***p < vs placebo

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 4.

GLP-1 Agonists and Cardiovascular Health

Nat. Rev. Nephrol. doi: /nrneph

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 3.

INCRETINS In response to equivalent hyperglycemic stimuli, ORAL glucose elicits a greater insulin response than IV glucose Glucagon-like Peptide 1 (GLP-1)

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Summary of DURATION development program select efficacy results: absolute difference in change in A1C, body weight, systolic blood pressure, and LDL cholesterol.

Antihyperglycemic therapy in type 2 diabetes: general recommendations

Pramlintide Synthetic analog of the β-cell hormone amylin

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

Glucose homeostasis: roles of insulin, glucagon, amylin, and GLP-1.

Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

ADA/EASD general recommendations for type 2 diabetes management (1).

Range of mean changes from baseline in A1C in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists.

Adjusted OR and SE for BMI≥30 kg/m2, BMI 25–29. 9 kg/m2, HbA1c≥6

Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 6.

Effect of metformin on glycemic control, insulin secretion, and insulin sensitivity in T2D. Effect of metformin on glycemic control, insulin secretion,

Incretin Physiology in Type 2 Diabetes Mellitus

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

The effect of VSG on body weight and body fat in GLP-1r KO mice.

Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).

Glycemic control and body weight over 52 weeks.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Adjusted OR and SE for BMI≥30 kg/m2, BMI 25–29. 9 kg/m2, HbA1c≥6

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.

Presentation transcript:

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4

DPP-4 Inhibition and Plasma Levels of GLP-1 DPP-4 inhibition prevents the degradation of active GLP-1 but does not increase GLP-1 secretion nor prevent the kidney from rapidly clearing GLP-1 DPP-4 inhibition also acutely decreases L-cell secretion of GLP-1, most likely via negative feedback inhibition of the L-cell. During a meal, total GLP-1 decreases but active GLP-1 (7-36) increases

DPP-4 Inhibition and Plasma Levels of GLP-1 DPP-4 inhibition prevents the degradation of active GLP-1 but does not increase GLP-1 secretion nor prevent the kidney from rapidly clearing GLP-1

Exendin-4: A GLP-1R Agonist

Exenatide Restores First-Phase Insulin Secretion in Type 2 Diabetes

Effect of Exenatide Versus Glargine Insulin on Insulin Secretion in Type 2 Diabetes Subjects:55 type 2 diabetes Age=58 years; BMI=30.5 kg/m 2 Diabetes duration=4.8 years A1C=7.5%; FPG=9.1 mM Study Design:Exenatide*(n=36) vs glargine (n=33) Treatment goal = A1C ≤7.0% Actual A1C=6.8±0.1% ∆ Body wt (kg)=+1.0 glargine vs -3.6 exenatide Study Duration:1 Year *5-10 µg BID up to µg TID.

C-Peptide Secretion During Hyperglycemic Clamp After 1 Year of Exenatide (10 µg BID-15 µg TID) vs Glargine Insulin Therapy to Reduce A1C <7.0%

Effect of Exenatide vs Glargine on Postmeal Blood Glucose Excursion

Summary of Exenatide (30 Weeks) Pivotal Studies (N=1446): Effect on Postprandial Glucose

Summary of Combined Exenatide (30 Weeks) Pivotal Studies (N=1446): Effect on Fasting Plasma Glucose Concentration P< Change in FPG From Baseline (mg/dL) P<.0001 Exenatide 5 µg BID (n=480) Exenatide 10 µg BID (n=483) 0 Placebo (n=483) DeFronzo R, et al. Diabetes Care May;28(5): Buse J, et al. Diabetes Care Nov;27(11): Kendall, DM et al. Diabetes Care May;28(5):

Actions of DPP-4 Inhibitors and GLP-1 Receptor Agonists in Regulating Glucose Homeostasis